|Bid||6.00 x 38800|
|Ask||6.35 x 4000|
|Day's Range||6.19 - 6.35|
|52 Week Range||5.27 - 14.15|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 6, 2018 - Aug 10, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.44|
The biotech analysts at Cantor Fitzgerald have a packed calendar: here are some of the dates they’re tracking and why they’re important. Mallinckrodt PLC (NYSE: MNK ) is expected to release Phase 4 interim ...
After topping the $110 level in March 2018, shares of Nektar Therapeutics (NASDAQ:NKTR) are in a downtrend. It is worth noting that even though Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) and Endo International PLC (NASDAQ:ENDP) are starting to attract investors, NKTR stock is more attractive because of the drug’s inherent properties. Nektar collaborated with Bristol-Myers Squibb Company (NYSE:BMY) to develop NKTR-214 in clinical trials.
LONDON, UK / ACCESSWIRE / May 9, 2018 / If you want access to our free research report on Lannett Co., Inc. (NYSE: LCI), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=LCI as the Company's latest news hit the wire. On May 7, 2018, the Company announced that it has acquired 23 approved and one pending drug product applications from a subsidiary of Endo International PLC (NASDAQ: ENDP) ("Endo") for an upfront payment plus future milestone payments.
Some pharma stocks are on the rise today, following earnings and Shire's (SHPG) $62 billion takeover deal, but the goodwill didn't spread to all regions of the sector. Valeant Pharmaceuticals International (VRX) delivered a beat-and-raise first quarter, saying it earned 89 cents a share on revenue of $2 billion, while analysts expected EPS of 60 cents on revenue of $1.95 billion. For the full year, it now sees revenue of $8.15 billion to $8.35 billion, up from its previous $8.1 billion-$8.3 billion range, and above the $8.23 billion consensus estimate.
Endo International Plc on Tuesday posted a quarterly profit that beat Wall Street estimates as the company makes good on plans to pivot to its injectables and branded drugs businesses, while remaining "laser-focused" on paying down long-term debt. As large retail pharmacies wield increasing heft in negotiating down prices of generic drugs, Endo has pushed to expand other segments of its business, such as sterile injectables and medical aesthetics, while discontinuing sales of products that are not as profitable. "We're all about going forward right now," Chief Executive Officer Paul Campanelli said on a conference call.
Investors need to pay close attention to Endo International (ENDP) stock based on the movements in the options market lately.
Endo International PLC shares rose 5% in premarket trade Tuesday after the company reported first-quarter profit and revenue that came in above FactSet expectations. The company also affirmed its 2018 revenue guidance of $2.6 billion to $2.8 billion and 2018 guidance for adjusted EPS from continuing operations of $2.15 to $2.55.
Drugmaker Endo International Plc reported a bigger quarterly loss on Tuesday, hurt by an impairment charge and a fall in sales of its generic drugs. The company recorded an asset impairment charge of $448.4 ...
DUBLIN , May 8, 2018 /PRNewswire/ -- First-quarter 2018 revenues of $701 million First-quarter 2018 Branded Specialty Products revenues increased 7 percent versus first-quarter 2017 to $112 million First-quarter ...
Financial terms of the deal, which includes another product that will soon be submitted for approval from the Food and Drug Administration, were not disclosed.
DUBLIN , May 2, 2018 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that Paul Campanelli , President and CEO, will participate in a fireside chat at the UBS Global Healthcare Conference ...
LONDON, UK / ACCESSWIRE / April 30, 2018 / Active-Investors.com has just released a free research report on Endo International PLC (NASDAQ: ENDP ). If you want access to this report all you need to do ...
DUBLIN, April 27, 2018 /PRNewswire/ -- Endo International plc (ENDP) today announced the presentation of clinical data from a Phase 2b investigational study of collagenase clostridium histolyticum (CCH) for the treatment of cellulite. Dr. Lawrence Bass, a New York City-based, board-certified plastic surgeon, will present the data this afternoon during the Premier Global Hot Topics session, a highlight of The Aesthetics Meeting 2018, the annual meeting of the American Society for Aesthetic Plastic Surgery (ASAPS), held at the Marriott Marquis in New York City. "Hot Topics, one of the most popular sessions at the annual meeting, is about new and emerging technologies in aesthetic plastic surgery," said ASAPS-member Dr. Bass.
The Somerset, N.J., company that Endo is buying specializes in sterile injectable products. The deal also include a manufacturing facility in India.
DUBLIN, April 26, 2018 /PRNewswire/ -- Endo International plc (ENDP) today announced that it has reached definitive agreements to acquire Somerset Therapeutics, LLC, a New Jersey based specialty pharmaceutical company that develops and markets sterile injectable and ophthalmic drugs for the U.S. marketplace, and the business of its India based affiliate Wintac Limited, which operates as Somerset Therapeutics' contract developer and manufacturer. Endo is paying approximately $190 million in total for Somerset Therapeutics and Wintac's business. Together, the acquisitions will secure for Endo's Par Sterile injectable business Somerset Therapeutics' commercial and pipeline products as well as Wintac's manufacturing capabilities for those products.
Paladin Labs Inc. Announces Launch of New Indication for XIAFLEX® (Collagenase Clostridium Histolyticum), Broadening Its Use to the Treatment of Appropriate Patients with Peyronie's Disease
Paladin Labs Announces the Launch of Unisom® Snore Relief, the Only Natural Health Product Throat Spray Available in Canada to Help Relieve Symptoms Associated with Snoring
After looking at Endo International plc’s (NASDAQ:ENDP) latest earnings announcement (31 December 2017), I found it useful to revisit the company’s performance in the past couple of years and assessRead More...
DUBLIN , April 17, 2018 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today announced that its subsidiaries, Par Pharmaceutical, Inc. and Par Sterile Products, LLC, have received a Notice Letter ...
Investors in Endo International (ENDP) need to pay close attention to the stock based on moves in the options market lately.
DUBLIN , April 13, 2018 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) will announce its first-quarter 2018 financial results on May 8, 2018 and members of its senior management team will host ...
NEW YORK, April 09, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...